CMV pp52 Protein

<strong>CMV pp52 Protein</strong>_x000D_ <strong>Catalog number:</strong> B2011986_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 1 mg_x000D_ <strong>Molecular Weight or Concentration:</strong> 1.87 mg/mL_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20 °C_x000D_ <strong>Keywords:</strong> Cytomegalovirus pP52 protein,UL44 protein, CMV Pp52 antigen, Cytomegalovirus UL44 protein, CMV Pp52 protein_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Yong MK, Lewin SR, Manuel O. Immune Monitoring for CMV in Transplantation Curr Infect Dis Rep. 2018 Mar 14;20(4):4._x000D_ 2: García-Ríos E, Nuévalos M, Mancebo FJ, Pérez-Romero P. Is It Feasible to Use CMV-Specific T-Cell Adoptive Transfer as Treatment Against Infection in SOT Recipients? Front Immunol. 2021 Apr 23;12:657144._x000D_ 3: Ziemann M, Thiele T. Transfusion-transmitted CMV infection - current knowledge and future perspectives Transfus Med. 2017 Aug;27(4):238-248._x000D_ 4: Prakash K, Chandorkar A, Saharia KK. Utility of CMV-Specific Immune Monitoring for the Management of CMV in Solid Organ Transplant Recipients: A Clinical Update Diagnostics (Basel). 2021 May 13;11(5):875._x000D_ 5: Apiwattanakul N, Hongeng S, Anurathapan U, Pakakasama S, Srisala S, Klinmalai C, Andersson BS. CMV-Reactive NK Cells in Pediatric Post-Hematopoietic Stem Cell Transplant Transplant Proc. 2020 Jan-Feb;52(1):353-359._x000D_ 6: Roback JD. CMV and blood transfusions Rev Med Virol. 2002 Jul-Aug;12(4):211-9._x000D_ 7: Mo W, Liang Y, Wang C, Zhang Y. A Simplified CMV-specific T Cell Transfer Targeting Drug-resistant CMV Retinitis Ocul Immunol Inflamm. 2021 Mar 18:1-3._x000D_ 8: Paar DP, Pollard RB. Immunotherapy of CMV infections Adv Exp Med Biol. 1996;394:145-51._x000D_ 9: Kirisri S, Vongsakulyanon A, Kantachuvesiri S, Razonable RR, Bruminhent J. Predictors of CMV Infection in CMV-Seropositive Kidney Transplant Recipients: Impact of Pretransplant CMV-Specific Humoral Immunity Open Forum Infect Dis. 2021 Apr 17;8(6):ofab199._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/33749938">10: Veit T, Pan M, Munker D, Arnold P, Dick A, Kunze S, Meiser B, Schneider C, Michel S, Zoller M, Böhm S, Walter J, Behr J, Kneidinger N, Kauke T. Association of CMV-specific T-cell immunity and risk of CMV infection in lung transplant recipients Clin Transplant. 2021 Jun;35(6):e14294. </a>_x000D_ _x000D_ <strong>Products Related to CMV pp52 Protein can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>